ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > TL1A

TL1A

概要

Name:Tumor necrosis factor superfamily member 15
Target Synonym:VEGI192A,Vascular Endothelial Cell Growth Inhibitor,TNF Superfamily Ligand TL1A,TNFSF15,Tumor Necrosis Factor (Ligand) Superfamily, Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TL1A,Tumor Necrosis Factor Ligand 1B,TNLG1B,TNF Superfamily Member 15,Tumor Necrosis Factor Superfamily Member 15,TL1,TNF Ligand-Related Molecule 1,Tumor Necrosis Factor Ligand Superfamily Member 15,MGC129934,MGC129935
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

CHEK-ATP142-Cell-based assay
 TL1A FACS

Expression analysis of human TL1A on HEK293/Human TL1A Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human TL1A Stable Cell Line or negative control cell using anti-human TL1A Antibody followed by staining with PE anti-human IgG Fc Antibody.

TLA-H5243-Cell-based assay
 TL1A CELL

Response to human TL1A protein (FOLD).
This reporter cell was incubated with serial dilutions of human TL1A protein (Cat.No.TLA-H5243). The max induction fold was approximately 40.12.

TLA-H5248-SPR
 TL1A SPR

Human TL1A Protein (E120A, E122A, M217A), His Tag (Cat. No. TLA-H5248) immobilized on CM5 Chip can bind Human DcR3, Fc Tag (Cat. No. TNB-H5255) with an affinity constant of 2.36 nM as determined in a SPR assay (Biacore 8K) (QC tested).

TLA-H52Q1-SPR
 TL1A SPR

Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) immobilized on CM5 Chip can bind Biotinylated Human TL1A Protein, His,Avitag (Cat. No. TLA-H52Q1) with an affinity constant of 97.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

TL1A, VEGI-251, TNFSF15

Background

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Tulisokibart PRA-023; MK-7240; PRA023 Phase 3 Clinical Prometheus Biosciences Inc, Merck Sharp & Dohme LLC Inflammatory Bowel Diseases; Lung Diseases, Interstitial; Colitis, Ulcerative; Scleroderma, Diffuse; Crohn Disease Details
RVT-3101 PF-06480605; PF 6480605; RVT-3101 Phase 2 Clinical Pfizer Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
TEV-48574 TEV-48574 Phase 2 Clinical Teva Pharmaceutical Industries Ltd Colitis, Ulcerative; Asthma; Crohn Disease Details
Next-generation anti-TL1A antibody(Telavant) Phase 1 Clinical Telavant Inc Fibrosis; Inflammation Details

This web search service is supported by Google Inc.

totopphone